A detailed history of Deutsche Bank Ag\ transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 46,571 shares of MDGL stock, worth $10.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
46,571
Previous 46,546 0.05%
Holding current value
$10.1 Million
Previous $12.4 Million 4.97%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$193.33 - $291.99 $4,833 - $7,299
25 Added 0.05%
46,571 $13 Million
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $2.2 Million - $3.64 Million
-12,851 Reduced 21.64%
46,546 $12.4 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $1.87 Million - $3.68 Million
15,526 Added 35.39%
59,397 $13.7 Million
Q3 2023

Nov 09, 2023

BUY
$146.04 - $225.78 $998,913 - $1.54 Million
6,840 Added 18.47%
43,871 $6.41 Million
Q2 2023

Aug 14, 2023

SELL
$203.88 - $312.0 $4.52 Million - $6.91 Million
-22,149 Reduced 37.43%
37,031 $8.55 Million
Q1 2023

May 15, 2023

SELL
$231.06 - $307.08 $620,858 - $825,123
-2,687 Reduced 4.34%
59,180 $14.3 Million
Q4 2022

Feb 13, 2023

BUY
$58.39 - $296.54 $608,248 - $3.09 Million
10,417 Added 20.25%
61,867 $18 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $125,864 - $165,221
2,078 Added 4.21%
51,450 $3.34 Million
Q2 2022

Aug 11, 2022

SELL
$58.04 - $100.2 $17,760 - $30,661
-306 Reduced 0.62%
49,372 $3.53 Million
Q1 2022

May 13, 2022

BUY
$55.89 - $101.89 $798,053 - $1.45 Million
14,279 Added 40.34%
49,678 $4.88 Million
Q4 2021

Feb 11, 2022

BUY
$72.34 - $95.09 $1.05 Million - $1.38 Million
14,554 Added 69.82%
35,399 $3 Million
Q3 2021

Nov 04, 2021

BUY
$78.35 - $105.02 $56,255 - $75,404
718 Added 3.57%
20,845 $1.66 Million
Q2 2021

Aug 11, 2021

SELL
$97.2 - $137.59 $10.1 Million - $14.3 Million
-104,049 Reduced 83.79%
20,127 $1.96 Million
Q1 2021

May 13, 2021

BUY
$108.54 - $125.2 $11.3 Million - $13.1 Million
104,550 Added 532.71%
124,176 $14.5 Million
Q4 2020

Feb 16, 2021

BUY
$110.06 - $133.7 $235,968 - $286,652
2,144 Added 12.26%
19,626 $2.18 Million
Q3 2020

Nov 12, 2020

BUY
$99.78 - $124.21 $10,476 - $13,042
105 Added 0.6%
17,482 $2.08 Million
Q2 2020

Aug 13, 2020

SELL
$60.13 - $125.71 $3.49 Million - $7.3 Million
-58,097 Reduced 76.98%
17,377 $1.97 Million
Q1 2020

May 14, 2020

SELL
$66.76 - $93.49 $333,265 - $466,702
-4,992 Reduced 6.2%
75,474 $5.04 Million
Q4 2019

Feb 14, 2020

BUY
$84.28 - $118.5 $5.58 Million - $7.84 Million
66,198 Added 463.96%
80,466 $7.33 Million
Q3 2019

Nov 14, 2019

BUY
$84.4 - $106.53 $20,931 - $26,419
248 Added 1.77%
14,268 $1.23 Million
Q2 2019

Aug 14, 2019

SELL
$91.13 - $142.5 $224,179 - $350,550
-2,460 Reduced 14.93%
14,020 $1.47 Million
Q1 2019

May 15, 2019

SELL
$103.48 - $143.84 $722,704 - $1 Million
-6,984 Reduced 29.76%
16,480 $2.06 Million
Q4 2018

Feb 14, 2019

SELL
$94.77 - $215.54 $3.93 Million - $8.93 Million
-41,448 Reduced 63.85%
23,464 $2.64 Million
Q3 2018

Dec 21, 2021

BUY
$207.3 - $300.31 $4.47 Million - $6.48 Million
21,572 Added 49.77%
64,912 $13.9 Million
Q3 2018

Nov 14, 2018

BUY
$207.3 - $300.31 $1.23 Million - $1.78 Million
5,911 Added 15.79%
43,340 $9.28 Million
Q2 2018

Apr 21, 2020

BUY
$101.55 - $313.9 $213,762 - $660,759
2,105 Added 5.96%
37,429 $10.5 Million
Q2 2018

Aug 14, 2018

SELL
$101.55 - $313.9 $1.67 Million - $5.17 Million
-16,482 Reduced 31.81%
35,324 $9.88 Million
Q1 2018

Oct 18, 2019

BUY
$93.35 - $149.04 $2.01 Million - $3.2 Million
21,499 Added 70.94%
51,806 $6.05 Million
Q1 2018

May 15, 2018

BUY
$93.35 - $149.04 $1.56 Million - $2.49 Million
16,682 Added 122.44%
30,307 $3.54 Million
Q4 2017

Feb 14, 2018

SELL
$39.35 - $97.37 $1.13 Million - $2.8 Million
-28,756 Reduced 67.85%
13,625 $1.25 Million
Q3 2017

Nov 14, 2017

BUY
$15.48 - $46.19 $656,057 - $1.96 Million
42,381
42,381 $1.91 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.71B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.